Company Description
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment.
The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 4, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,779 |
| CEO | Dr. Helmy Eltoukhy Ph.D. |
Contact Details
Address: 3100 Hanover Street Palo Alto, California 94304 United States | |
| Phone | 855 698 8887 |
| Website | guardanthealth.com |
Stock Details
| Ticker Symbol | GH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576280 |
| CUSIP Number | 40131M109 |
| ISIN Number | US40131M1099 |
| Employer ID | 45-4139254 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. AmirAli Talasaz Ph.D. | Co-Chief Executive Officer and Director |
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-Chief Executive Officer and Chairman |
| Michael Bell | Chief Financial Officer |
| Darya Chudova | Chief Technology Officer |
| Dr. Craig Eagle M.D. | Chief Medical Officer |
| Christopher Freeman | Chief Commercial Officer |
| Kumud Kalia | Chief Information Officer |
| Zarak Khurshid | Vice President of Investor Relations |
| John G. Saia | Chief Legal Officer and Corporate Secretary |
| Jennifer Higgins | Senior Vice President of Public Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 23, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 424B5 | Filing |
| Aug 7, 2024 | 10-Q | Quarterly Report |